Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.

Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.

Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.

Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.

Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.

Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.

Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.

Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.

Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.

Abstract: A process for treating a first metal, manganese-containing ore comprising contacting the manganese-containing ore with an aqueous, acidic composition and a material containing at least one metal sulfide at conditions effective to (1) chemically reduce at least a portion of the manganese, (2) solubilize at least a portion of the metal from the metal sulfide, and (3) at least partially liberate the first metal from the ore; and recovering the first metal from the ore. The use of Thiobacillus ferrooxidans and/or added ferric ion in the contacting step are also disclosed.

Abstract: A process for recovering at least one first metal from a metal sulfide-containing ore comprising contacting the ore with an aqueous, acidic composition and at least one reducible manganese-containing material at conditions effective (1) to chemically reduce the manganese, (2) solubilize at least a portion of the metal from the sulfide, and (3) at least partially liberate the first metal from the ore; and recovering the first metal from the ore. The use of added ferric ion and/or Thiobacillus ferrooxidans bacteria in the above-noted contacting is also disclosed.

Abstract: A process for separating precious metals from a roaster calcine leach residue from a process wherein copper or zinc sulfides are roasted to produce a copper or zinc calcine; the calcine is leached with an aqueous sulfuric acid leaching solution to produce a copper or zinc-containing leaching solution and a roaster calcine leach residue and the copper or zinc-containing leaching solution is separated from the roaster calcine leach residue wherein the process comprises:(a) intimately contacting the roaster calcine leach residue with an aqueous sulfuric acid leach solution containing from about 5 to about 200 grams per liter of sulfuric acid to produce a slurry of leach solution and roaster calcine leach residue and to dissolve precious metal from roaster calcine leach residue;(b) adding copper or zinc sulfide solids to the mixture of leach solution and said roaster calcine each residue;(c) agitating the copper or zinc sulfide solids in intimate contact with the mixture of leach solution and roaster calcine leac